rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    AUPH
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Aurinia: Paying For Growth That Is Already Fading (NASDAQ:AUPH)
      Nov 10Seeking AlphaAUPH
      Analysts Are Bullish on These Healthcare Stocks: Aurinia Pharmaceuticals (AUPH), AbbVie (ABBV)

      Detailed price information for Abbvie Inc (ABBV-N) from The Globe and Mail including charting and trades.

      Nov 4The Globe and MailAUPHABBV
      Aurinia lifts 2026 guidance as LUPKYNIS growth, cash flow and pipeline momentum build

      Tipranks Press Release.

      Oct 31The Globe and MailAUPH
      Aurinia earnings missed, revenue fell short of estimates
      Oct 30Investing.comAUPH
      Aurinia Pharmaceuticals stock falls 3% on Q3 miss, soft guidance
      Oct 30Investing.comAUPH
      Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
      Oct 30Yahoo FinanceAUPH
      Aurinia: Q3 Earnings Snapshot
      Oct 30Yahoo FinanceAUPH
      Aurinia earnings on deck as Lupkynis growth momentum tested
      Oct 28Investing.comAUPH
      Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline

      Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Oct 27Yahoo FinanceAUPH
      TD Cowen raises Aurinia Pharmaceuticals price target on cost outlook
      Oct 21Investing.comAUPH
      Aurinia: Lupkynis Is A Cash Cow, But Competition And Patent Risks Cap The Upside (AUPH)
      Sep 22Seeking AlphaAUPH
      Aurinia’s (AUPH) Profits Surge While Its One Drug Just Got Company

      On August 6, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and six months ended June 30, and the numbers showed a company converting revenue growth into a much bigger jump in profit. Total revenue climbed 19% to $83.2 million for the quarter, but net income jumped 74% to $37.4 million, nearly four […]

      Sep 16Yahoo FinanceAUPH
      Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?

      Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurinia’s patents covering its flagship oral lupus nephritis drug, LUPKYNIS, are valid, enforceable, and infringed by its proposed generic 7.9 mg voclosporin product. Teva agreed to delay generic commercialization until […]

      Aug 28Yahoo FinanceAUPHTEVA
      Aurinia Pharmaceuticals Chief Legal Officer Trades $355K In Company Stock
      Aug 26BenzingaAUPH

      This is the newest page. Registered accounts read further back.